Tagraxofusp induces a rapid restoration of normal hematopoiesis in patients with newly-diagnosed BPDCN

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy that derives from plasmacytoid dendritic cells. During ASH 2024, Prof Dr Marina Konopleva from the Albert Einstein College of Medicine (Bronx, NY, USA) presented the results of a sub analysis of a phase II study evaluating the anti-CD123 agent tagraxofusp as first line treatment for patients with BPDCN. This analysis confirmed that tagraxofusp induces rapid and durable responses in this setting. Interestingly, the treatment with tagraxofusp did not induce cumulative myelosuppression, but instead restored the normal hematopoiesis in patients with BPDCN. As such, these findings provide further support for tagraxofusp monotherapy as a frontline treatment for patients with this rare hematological malignancy. Furthermore, the excellent tolerability of this agent makes it an attractive combination partner for other agents in the treatment of other CD123+ hematologic malignancies.